Global AI-driven Peptide Drug Discovery Platform Market Strategic Research Report

Scope of the Report

The global AI-driven Peptide Drug Discovery Platform market size is predicted to grow from US$ 762 million in 2025 to US$ 1,430 million in 2032; it is expected to grow at a CAGR of 9.6% from 2026 to 2032.

AI-driven Peptide Drug Discovery Platforms are tools that use artificial intelligence (AI) technology to accelerate and optimize the discovery and development process of peptide drugs. These platforms typically combine computational biology, machine learning, deep learning and other technologies to improve the efficiency of identifying, designing, optimizing and validating drug candidate molecules.

The global AI-driven peptide drug R&D market is in a period of rapid growth, with the core driving force coming from the high failure rate of traditional peptide R&D (over 90% elimination rate in the preclinical stage) and the significant advantages of AI technology in reducing costs and increasing efficiency (shortening the early R&D cycle by 50%). North America occupies a dominant position (about 48% market share in 2023), mainly due to the concentration of leading companies such as Insilico Medicine and Schrödinger and active biopharmaceutical venture capital; the Asia-Pacific region has the fastest growth rate (CAGR of 29%), thanks to China's "14th Five-Year Plan for Bioeconomic Development" policy support for AI pharmaceuticals and technological breakthroughs by local companies such as Tai Technology. In the sub-sectors, tumor treatment (PDC drug development) and anti-infective drugs (antimicrobial peptide optimization) account for more than 60% of the market share, while metabolic diseases and neurological diseases have become emerging growth poles due to breakthroughs in GLP-1 analogs and blood-brain barrier penetration technology. The challenges faced by the industry are the low clinical conversion rate (only 7% of AI-designed drug candidates enter Phase II clinical trials) and data barriers (data closure of pharmaceutical companies limits model training), but the deepening cooperation between multinational pharmaceutical companies and AI platforms (such as Pfizer and Cyclica jointly developing peptide vaccines) is promoting the openness of the ecosystem. In the future, peptide-nucleic acid conjugates (PepRNA) and AI-driven fully automated laboratories (such as the Strateos cloud-based robotics platform) may reshape the industry's competitive landscape.

This report presents a comprehensive overview of the global AI-driven Peptide Drug Discovery Platform market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Design and Generation Platform
• Screening and Optimization Platform
• Data-driven Platform
• Others

Segment by Application

• Scientific Research
• Pharmaceuticals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global AI-driven Peptide Drug Discovery Platform market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Scientific Research, Pharmaceuticals evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact